semaglutide and stroke Efficacy of glucagon-like peptide-1 receptor agonists for prevention of among patients with without diabetes: A meta-analysis with the SELECT and FLOW trails semaglutide subcutaneous Semaglutide, other obesity

Preparing for Your First Tirzepatide Injection 1

While other programs offer vague promises, we provide a medically-backed strategy that empowers you to finally break the cycle of yo-yo dieting and build a foundation for lifelong health

The brain, however, is a sugar hound, using as much as 20 percent of the glucose we produce

1,2 The results are consistent with actions taken by the European Medicines Agency (EMA) in June 2025, when the agency classified NAION as a very rare side effect of semaglutide and recommended product labeling updates. Epidemiologic data reviewed by the EMA suggested an approximately twofold increased risk in adults with type 2 diabetes, corresponding to roughly one additional case per 10,000 person-years of treatment. The agency advised that patients with sudden vision loss or rapidly worsening eyesight seek immediate medical attention and discontinue treatment if NAION is confirmed. READ MORE: Blinding Disease-Weight Loss Drug Link: EMA Announces Start of Semaglutide Investigation Study strengths Methodologically, the VA study offers several strengths: The analysis leveraged the largest integrated health care system in the United States, with medication exposure confirmed through pharmacy dispensing records rather than prescription data alone